The economist thinks the Fed ought to pay more attention to financial markets when setting interest rates.The Fedread more
Kohl's, J.C. Penney and Nordstrom release disappointing earnings news, putting a damper on their sector.Retailread more
Bezos's comments give a rare glimpse into his interest in the auto industry. Amazon recently invested in two self-driving start-ups.Technologyread more
While investing often seems like a contrarian game where going against the flow feels like the better bet, the reality is that investors who bought the most-favored stocks...Hedge Fundsread more
Talks between the world's two largest economies have stalled after each nation lobbied higher tariffs on the other's imports.Traderead more
A Chinese official in Hong Kong is urging the quick passage of legal measures to allow fugitives to be transferred to the mainland.China Politicsread more
GAC Motor said its delaying its launch in the U.S. but had no timeline when it could launch there.Autosread more
Shares in Asia were higher in Wednesday morning trade following a positive finish overnight on Wall Street, though trade tensions continued to linger between the U.S. and...Asia Marketsread more
See which stocks are posting big moves after the bell on Tuesday, May 21.Market Insiderread more
CBS plans to renew discussions for Starz with Lions Gate in the coming weeks, according to people familiar with the matter. If a deal happens, the remainder of Lions Gate...Technologyread more
The United States sees signs the Syrian government may be using chemical weapons, including an alleged chlorine attack on Sunday in northwest Syria, the State Department said...Defenseread more
fall@ (Adds details on the trial)
May 17 (Reuters) - AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial.
The company's shares fell 1.8 percent to $78.10 before the bell.
An independent data monitoring committee recommended the study be stopped due to "lack of survival benefit" for patients receiving the treatment Depatux-M when compared with a placebo, AbbVie said.
Depatux-M, when added to the standard regimen of radiation and temozolomide, failed to meet the main goal of achieving overall survival in newly diagnosed patients when compared to patients given a placebo along with radiation and temozolomide.
The trial has been testing the drug to treat an aggressive form of brain cancer known as glioblastoma.
About 17,760 people are estimated to die from brain and spinal cord tumors in the United States, in 2019, according to the American Cancer Society. (Reporting by Aakash Jagadeesh Babu in Bengaluru Editing by Saumyadeb Chakrabarty and Shounak Dasgupta)